Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range

Blood

Volumn 96, Issue 3, 2000, Pages 846-851

  Greinacher, A ^a   Eichler, P ^a   Lubenow, N ^a   Kwasny, H ^a   Luz, M ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LEPIRUDIN;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIMB AMPUTATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0034254793     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.3.846.015k09_846_851     Document Type: Article

References (27)

1. Heparin-induced thrombocytopenia: Towards consensus
2. Heparin-induced thrombocytopenia in patients treated with low- molecular-weight heparin or unfractionated heparin
3. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases
4. Pathogenicity of IgA and/or lgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia
5. Immune endothelial-cell injury in heparin-associated thrombocytopenia
6. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
7. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-hepanin complex as the major antigen
8. Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with platelets
9. Heparin-induced thrombocytopenia: Laboratory studies
10. Plasma P-selectin is increased in thrombotic consumptive platelet disorders
11. Sere from patients with heparin-induced thrombocytopenia generate platelet-derived microparticies with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
12. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
13. Limitations of conventional treatment options for heparin-induced thrombocytopenia
14. Treatment of severe venous thromboembolism with intravenous hirudin (HBW 023): An open pilot study
15. Hirudins: Antithrombin anticoagulants
16. Clot bound thrombin is protected from inhibition by heparin- antithrombin III but is susceptible to inactivation by antithrombin III- independent inhibitors
17. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors
18. Recombinant hirudin (lepirudin) provides effective and safe anticoagulation in patients with heparin-induced thrombocytopenia type I.I.: A prospective study
19. A rapid and sensitive test for diagnosing heparin associated thrombocytopenia
20. First workshop for detection of heparin-induced antibodies validation of the heparin-induced-platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA
21. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: A multicentre prospective dose-ranging randomized trial
22. A 14-year study of heparin-induced thrombocytopenia
23. Heparin-induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution
24. The pathogenesis of venous limb gangrene associated with heparin- induced thrombocytopenia
25. Monitoring anticoagulant therapy by activated partial thromboplastin time: Hirudin assessment
26. The whole blood ecarin clotting time assay allows rapid and accurate monitoring of the anticoagulant response of r-hirudin during cardio-pulmonary bypass